Paper Details

  1. Home
  2. Paper Details

Oral Atenolol versus Propranolol in the Treatment of Infantile Hemangioma: A Systematic Review and Meta-Analysis.

Author: AliMd Mokkaram, KaurHardeep, KumarSubodh, MahalmaniVidya M, MalikMuneer Abas, MedhiBikash, PattanshettiSwapnil Annasaheb, PetersNitin James, PrajapatManisha, SamujhRam, SarmaPhulen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Infantile hemangioma (IH) is a common benign vascular tumor in infants. Propranolol is considered first-line therapy but has side effects. This study aims to evaluate the safety and efficacy of atenolol, a selective b1-blocker, as an alternative treatment for IH.
Paper Details　
Original Abstract of the Article :
Infantile hemangioma (IH) is the most common benign vascular tumor of infancy. Propranolol is considered first-line therapy for IH. However, it is associated with side effects. Therefore, there was a need for alternative therapy. Atenolol, a selective b1-blocker may be free from such side effects. H...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208683/

データ提供：米国国立医学図書館（NLM）

Oral Atenolol vs. Propranolol: A Comparative Look at Treatments for Infantile Hemangioma

Infantile hemangioma (IH), a common benign vascular tumor, often requires medical intervention. Propranolol, a beta-blocker, is currently considered the first-line treatment for IH. However, concerns about potential side effects have led to the exploration of alternative therapies. This study focuses on comparing the safety and efficacy of atenolol, another selective beta-blocker, with propranolol in treating IH. The authors conducted a systematic review and meta-analysis of existing research to provide a more comprehensive understanding of the relative benefits and risks of these two medications.

Atenolol: A Promising Alternative for Treating Infantile Hemangioma

The study explores the potential of atenolol as a safe and effective alternative to propranolol for treating IH. The findings could lead to broader treatment options for patients with IH, potentially reducing the need for more invasive interventions.

Understanding the Options: Informed Decision-Making for Patients with Infantile Hemangioma

This research provides valuable insights for healthcare professionals and patients seeking treatment for IH. By understanding the relative benefits and risks of atenolol and propranolol, patients can make more informed decisions about their treatment options.

Dr. Camel's Conclusion

Just as a camel navigates a complex desert landscape, researchers are exploring the best treatment pathways for infantile hemangioma. This study offers a closer look at the comparative safety and efficacy of atenolol and propranolol, providing valuable insights for patients and healthcare professionals alike. With continued research and innovation, we can work towards finding the most effective and safest treatments for this common condition.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

35733601

DOI: Digital Object Identifier

PMC9208683

Related Literature

Article Analysis
・Side Effects of atenolol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.